In silico design of 3-methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione inhibitors against tuberculosis via docking and dynamics simulation techniques and pharmacokinetic evaluation
ASPET Discovery · 2026 · 2 · 100007
DOI: 10.1016/j.aspetd.2025.100007 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASPET Discovery, 2026. Verfasst von Maimuna Shehu Rufa’i und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tertiary Education Trust Fund.
Abstract (Originalsprache)
Due to growing medication resistance and a lack of effective treatment alternatives, tuberculosis (TB), which is caused by Mycobacterium tuberculosis, continues to pose a serious threat to world health. In TB drug discovery, the enzyme decaprenylphosphoryl-β-D-ribose oxidase (DprE1) is a proven and crucial therapeutic target. The in-silico creation of novel 3-Methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione derivatives as putative DprE1 inhibitors is the main emphasis of this research. To find strong candidates, a structure-based drug design strategy was used, utilizing pharmacokinetic analyses, molecular docking, and molecular dynamics (MD) simulations. Strong binding contacts of the proposed derivatives within the DprE1 active site were found by the molecular docking study, emphasizing crucial hydrogen bonds and hydrophobic interactions that cause target inhibition. MD simulations (250 ns) were conducted to evaluate the protein-ligand complexes' stability, flexibility, and conformational dynamics in order to validate docking results. Stable binding was shown by important measures such as root mean square deviation (RMSD) and root mean square fluctuation (RMSF). Calculations of binding free energy (MM/PBSA) measured the advantageous thermodynamics of ligand binding. Furthermore, the top candidates' drug-like qualities were validated by ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) predictions, guaranteeing advantageous pharmacokinetic and safety profiles. Several optimized compounds of 3-Methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione with significant potential as TB inhibitors were found by combining these in silico approaches. The results open the door for the creation of innovative anti-tubercular treatments and offer a foundation for additional experimental validation.
Förderung
- Tertiary Education Trust Fund
Zitieren
APA
Rufa’i, M. S., Abdalla, M., Abdulganiyyu, I. A., Ajala, A., Alahmadi, R. M., Awadalla, M. E., Abdulganiyyu, K., Mahe, A., Gwarzo, Y. S., & Kabir, N. (2026). In silico design of 3-methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione inhibitors against tuberculosis via docking and dynamics simulation techniques and pharmacokinetic evaluation. ASPET Discovery, 2, 100007. https://doi.org/10.1016/j.aspetd.2025.100007
Vancouver
Rufa’i MS, Abdalla M, Abdulganiyyu IA, Ajala A, Alahmadi RM, Awadalla ME, et al. In silico design of 3-methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione inhibitors against tuberculosis via docking and dynamics simulation techniques and pharmacokinetic evaluation. ASPET Discovery. 2026;2:100007. doi:10.1016/j.aspetd.2025.100007
BibTeX
@article{Rufai2026,
author = {Rufa’i, Maimuna Shehu and Abdalla, Mohnad and Abdulganiyyu, Ibrahim A. and Ajala, Abduljelil and Alahmadi, Reham M. and Awadalla, Maaweya E. and Abdulganiyyu, Khadija and Mahe, Asma’u and Gwarzo, Yahaya Sa’id and Kabir, Nafisatu},
title = {In silico design of 3-methyl-3H-naphtho[1,2,3-de]quinoline-2,7-dione inhibitors against tuberculosis via docking and dynamics simulation techniques and pharmacokinetic evaluation},
journal = {ASPET Discovery},
year = {2026},
volume = {2},
pages = {100007},
doi = {10.1016/j.aspetd.2025.100007}
}
EUVIMED